Table 1 Population characteristics, ART status, and regimens

From: HIV transmission dynamics and population-wide drug resistance in rural South Africa

 

All (n = 1050)

ART-Naïve (n = 467)

Art-experienced (n = 583)

Age group (years)

15–24

218 (20.8%)

116 (24.8%)

102 (17.5%)

25–34

378 (36.0%)

189 (40.5%)

189 (32.4%)

35–44

261(24.9%)

99 (21.2%)

162 (27.8%)

45–54

147 (14.0%)

101 (21.6%)

46 (7.9%)

>55

74 (7.0%)

45 (9.6%)

29 (5.0%)

Sex (assigned at birth)

Female

693 (66.0%)

298 (63.8%)

395 (67.8%)

Male

357 (34.0%)

169 (36.2%)

188 (32.8%)

Currently on ART?

Yes

 

–

603a

No

 

–

34

Unknown

 

–

565

ART regimen

NRTI + NNRTI

  

348 (89.5%)

TDF, FTC, EFV

 

–

329

TDF, EFV, 3TC

 

–

5

AZT, EFV, 3TC

 

–

5

ABC, EFV, 3TC

 

–

1

d4T, EFV, 3TC

 

–

1

TDF, FTC, EFZ

 

–

1

TDF, NVP, 3TC

 

–

3

AZT, NVP, 3TC

 

–

2

TDF, FTC, NVP

 

–

1

NRTI + PI

 

–

27 (6.9%)

TDF, 3TC, LPV

 

–

14

AZT, 3TC, LPV

 

–

9

ABC, 3TC, LPV

 

–

2

TDF, FTC, LPV

 

–

1

TDF, ATV, LPV

 

–

1

NRTI + INSTI

 

–

10 (2.6%)

TDF, 3TC, DTG

 

–

10

  1. Data from 1202 participants with associated metadata for whom blood samples were collected and sent to the University of Oxford for sequencing. Of those, 1050 were successfully sequenced and analysed.
  2. ABC abacavir, EFV efavirenz, FTC emtricitabine, TDF tenofovir, 3TC lamivudine, LPV/r lopinavir/ritonavir, DTG dolutegravir, d4T stavudine, NVP nevirapine, INSTI integrase strand transfer inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, NRTI nucleoside/nucleotide reverse transcriptase inhibitors, PI protease inhibitors.
  3. aParticipant is currently taking ART, but regimens were unknown in 274 participants.
Back to article page